K
KYTX
vs
S&P 500
S&P 500
Over the past 12 months, KYTX has significantly outperformed S&P 500, delivering a return of +167% compared to the S&P 500's +12% growth.
Stocks Performance
KYTX vs S&P 500
Performance Gap
KYTX vs S&P 500
Performance By Year
KYTX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Kyverna Therapeutics Inc
Glance View
Kyverna Therapeutics Inc is a US-based company operating in industry. The company is headquartered in Emeryville, California. The company went IPO on 2024-02-08. Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The firm is focused on developing cell therapies for patients suffering from autoimmune diseases. The firm's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). The company intends to develop KYV-101 in two areas of autoimmune disease: rheumatology and neurology. Its initial rheumatology development focus is on lupus nephritis, and systemic sclerosis. The company is also actively developing an allogeneic, off-the-shelf approach to further broaden patient access. Its research-stage programs are focused on developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, and extend beyond CD19 CAR-T approaches, including regulatory T cells, or T-regs, and novel humanized CAR constructs developed by it for use in autoimmune diseases.
